Physician profile
Thomas M Brown
NPI 1285621763
$383.91
in general payments reported to CMS, 2019-2025
11 companies · $36.87 in 2025
The $36.87 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.00 · 2020: $14.13 · 2021: $20.92 · 2022: $18.95 · 2023: $105 · 2024: $118 · 2025: $36.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $87.12 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $80.78 | 2023-2025 | Veozah |
| Abbvie INC. | $55.73 | 2019-2022 | |
| Axsome Therapeutics, INC. | $33.42 | 2024 | Auvelity |
| Lundbeck LLC | $27.54 | 2023-2024 | Rexulti |
| Hologic Sales and Service, LLC | $20.92 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.63 | 2019 | |
| Daiichi Sankyo INC. | $16.38 | 2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2019 | |
| Avanos Medical | $14.13 | 2020 | |
| Mayne Pharma Commercial LLC | $13.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.